Early Psychological Intervention to Prevent Cardiovascular Event-Induced PTSD (REACH Sub-study)
Written Exposure Therapy to Prevent PTSD in Survivors of Acute Cardiovascular Events: A Pilot Randomized Clinical Trial
The overall purpose of this project is to determine the feasibility of conducting a randomized clinical trial that compares written exposure therapy with usual care among patients at risk for cardiovascular event-induced PTSD.
Patients hospitalized with acute cardiovascular events, including strokes, heart attacks, and cardiac arrest are at risk of developing post-traumatic stress disorder (PTSD) due to the trauma of the acute medical event. The goal of this study is to test the feasibility of conducting a randomized trial involving a psychological intervention to prevent the development of PTSD symptoms in patients at risk for PTSD. Patients who are admitted with these acute cardiovascular events will first be screened for PTSD risk factors while in-hospital after the index event. These risk factors will include elevated threat perceptions at the time of presentation to the hospital or early symptoms of PTSD due to the cardiovascular event. Patients at elevated risk for PTSD will then be randomized to the intervention group or usual care. Those assigned to the intervention will participate in 5 sessions of written exposure therapy in which they are asked to write about the experience of their cardiovascular event with guidance from a trained study clinician. At 1 month after discharge, all patients will be contacted by phone to complete a questionnaire that assesses PTSD symptoms related to the cardiovascular event. Descriptive statistics will be used to understand the feasibility of testing the written exposure therapy intervention as part of a larger, fully powered clinical trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Experiencing a life threatening cardiovascular event, such as a stroke, transient ischemic attack (TIA), acute coronary syndrome (ACS), or cardiac arrest has been found to be associated with PTSD symptoms in up to 1 in 3 survivors. Patients with elevated PTSD symptoms are at risk for lower medication adherence, increased readmissions, recurrent cardiovascular events, and worsened quality of life. Risk for recurrent cardiovascular events is especially high in the initial weeks after acute cardiovascular events, and existing epidemiological data suggest that PTSD symptoms increase this risk. Thus, intervening early to prevent PTSD symptoms prior to waiting the full one or more months to make a PTSD diagnosis may provide new opportunities for offsetting cardiovascular disease (CVD) risk. Despite these adverse consequence of cardiovascular event-induced PTSD, these patients are not currently being systematically screened or treated to prevent PTSD symptoms, in part because there is no evidence assessing the effect of early interventions in this patient population.
A growing number of studies have been evaluating early interventions after trauma to prevent PTSD. While there is no gold-standard intervention, psychological interventions grounded in trauma-focused, cognitive behavioral therapy (CBT) have shown promise in some populations. For example, compared to a supportive counseling control condition, CBT has been found to reduce PTSD symptom severity and incidence in individuals with acute stress disorder (ASD), an early manifestation of posttraumatic stress, detected within the first month of a traumatic event. Preliminary research suggests that an exposure-based CBT intervention delivered in the immediate aftermath of trauma for individuals meeting Criterion A of a Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) PTSD diagnosis may also hold promise for PTSD prevention. Acute cardiovascular events such as stroke and ACS as the source of trauma are inherently different from other forms of stressors that commonly lead to PTSD. As opposed to an external and past traumatic threat (e.g., combat, physical/emotional abuse), these events can represent an ongoing internal somatic threat. Accordingly, treatments for preventing PTSD such as the trauma-focused CBT interventions discussed above need to be formally evaluated in this distinct patient population before generalizing the findings from other patient populations. In particular, the willingness to engage in therapies to prevent or reduce PTSD symptoms may differ in this patient population. Few of these patients are actively seeking treatment. Many may not be aware of potential psychological symptoms that can begin or worsen after these events and may not perceive their psychological symptoms to be problematic. Hence, the acceptability of psychological interventions is particularly relevant in this patient population.
Written exposure therapy represents a promising intervention to prevent PTSD after cardiovascular events. Written exposure therapy is a brief exposure-based therapy, founded on the principles of Pennebaker and Beale's written disclosure procedure. The treatment protocol consists of 5 sessions, each comprising 30 minutes of writing. In each session, participants are instructed to write about their memory of the traumatic event with particular attention to the felt emotions and the meaning of the event. The initial session also incorporates psychoeducation and review of the rationale for the intervention by a study clinician. Sessions end with therapists' discussing how the writing session went. The rationale behind this exposure therapy is that there is a significant habituation of emotional reactivity to reminders of the traumatic event over repeated writing sessions. Consistent with this rationale, research suggests that these exposure writing sessions are associated with greater initial emotional and physiological reactivity and greater habituation of these responses over time compared to a control writing condition. A recent study showed that this brief psychotherapy approach was non-inferior to a more extensive CBT approach (cognitive processing therapy) for reducing PTSD symptoms in adults with PTSD. Written exposure therapy has also been shown to be effective at lowering PTSD symptoms in patients with motor vehicle accident-induced PTSD.
In contrast with more standard CBT interventions, written exposure therapy was designed to create a more acceptable exposure-based treatment option for PTSD that is easily disseminated and implemented. Like the promising trauma-focused CBT interventions for PTSD prevention, it is also exposure-based. In light of these qualities, written exposure therapy thus may be ideally suited for reducing PTSD symptoms in non-treatment seeking survivors of acute cardiovascular events. Key differences between written exposure therapy and other CBT approaches to treating PTSD include a lower frequency of sessions (~5) and no homework requirement, resulting in higher treatment completion compared to a more rigorous exposure-based therapy approach. Other advantages of written exposure therapy are that it requires a lower level of training from clinicians and less clinician time, which could facilitate dissemination.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Center for Behavioral Cardiovascular Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hospitalized with acute stroke, TIA, ACS, or cardiac arrest
- Enrolled in REACH-stroke, PHS, or REACH-cardiac arrest observational cohort studies
- Elevated ASD symptoms (ASD score >=28) and/or elevated threat perceptions during index hospitalization (ED threat score >=12)
Exclusion Criteria:
- Unavailable for follow-up for written exposure therapy sessions
- Unable to read and write in English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Early Psychological Intervention
Those assigned to Early Psychological Intervention will receive Written Exposure Therapy, a 5 session treatment in which participants write about their trauma event in a specified manner.
|
Written exposure therapy is a 5 session treatment in which participants write about their trauma event in a specified manner.
|
|
No Intervention: Usual care
Those assigned to usual care will complete study assessments but will not be referred to any psychological treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PTSD Checklist - Stressor Specific (PCL-S) Score
Time Frame: 1 month after hospital discharge
|
This is to measure PTSD symptoms due to the index cardiovascular event.
The PCL-S is self-report measure of the symptoms of PTSD.
Respondents rate how much they were bothered by 20 symptoms, each rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely), such that total scores range from 0-80.
The PCL-S (specific stressor) asks respondents about symptoms in relation to an identified stressful experience.
The PCL-S aims to link symptom endorsements to the index cardiovascular event
|
1 month after hospital discharge
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Subjects Completing the Written Exposure Therapy
Time Frame: Approximately 1 month after hospital discharge
|
This is to measure the feasibility of the therapy - completion to all 5 sessions among participants assigned to the intervention group
|
Approximately 1 month after hospital discharge
|
|
Adherent to Cardiovascular Medications
Time Frame: Approximately 1 month after hospital discharge
|
This is measured by the scoring from the Dose-Nonadherence questionnaire (3-items).
Participants were categorized as adherent if they reported "none of the time" on all 3 items.
Participants were categorized as nonadherent if they reported "at least some of the time" on any of the 3 items.
|
Approximately 1 month after hospital discharge
|
|
PHQ-8 Score
Time Frame: Baseline, 1 month after hospital discharge
|
This is to measure change in depressive symptoms.
The eight-item Patient Health Questionnaire depression scale (PHQ-8) is established as a valid diagnostic and severity measure for depressive disorders in large clinical studies.
Scores range from 0 - 24 and a score of 10 or greater is consistent with at least moderate depressive symptoms.
|
Baseline, 1 month after hospital discharge
|
|
Short Form Health Survey Version 2.0 (SF-12v2) Score
Time Frame: Approximately 6 months after hospital discharge
|
This is to measure quality of life. A health survey that uses 12 questions to measure functional health and well-being from the patient's point of view. This measure was not collected at 6-months in any participants due to the study being terminated early. |
Approximately 6 months after hospital discharge
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Ian Kronish, MD, Associate Professor of Medicine, Dept of Med Beh Cardiology
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AAAR7350-Q4612-R8497 substudy
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
NCT07208422RecruitingStroke | Stroke Hemorrhagic | Stroke Ischemic | Hemiparesis After Stroke
-
NCT07224178RecruitingHemorrhagic Stroke | Embolic Stroke of Undetermined Source | Ischemic Stroke, Cryptogenic | Recurrent Ischemic Stroke | Ischemic Stroke, Embolic
-
NCT07433972Not yet recruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke Survivors
-
NCT07236216RecruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke Patient
-
NCT04956185RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke Hemorrhagic
-
NCT05046106Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
NCT07199322Not yet recruitingStroke | Stroke Hemorrhagic | Upper Limb Rehabilitation | Stroke Ischemic
-
NCT07353203CompletedChronic Stroke | Subacute Stroke | Exoskeleton
-
NCT06127602RecruitingStroke, Ischemic | Stroke Hemorrhagic | Stroke, Cerebrovascular
-
NCT05815368RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke Hemorrhagic
Clinical Trials on Written Exposure Therapy
-
NCT04000217CompletedWritten Exposure Therapy | Imaginal Exposure Therapy
-
NCT06771817Active, not recruitingPost-Traumatic Stress Disorder in Adolescence | PTSD - Post Traumatic Stress Disorder | PTSD and Trauma-related Symptoms | Pregnancy and PTSD
-
NCT05553249CompletedPost Traumatic Stress Disorder
-
NCT05268367TerminatedStress Disorders, Post-Traumatic | Sexual Assault and Rape
-
NCT06042400CompletedLymphoproliferative Disorders | Anxiety | Metastatic Cancer | Solid Tumor Cancer | Post-traumatic Stress Symptoms | Fear of Cancer Progression
-
NCT05729789RecruitingPosttraumatic Stress Disorder
-
NCT05330442Active, not recruiting
-
NCT07576387Not yet recruitingPosttraumatic Stress Disorder (PTSD) | Borderline Personality Disorder (BPD)
-
NCT06394700RecruitingPTSD | Insomnia, Secondary
-
NCT06571513CompletedPost-traumatic Stress Disorder